Parallel analyses of HE4 and CA125 in the blood showed a statistically significant increase in the level of the marker in ovarian cancer compared with benign ovarian diseases (Figure 5B), and at advanced stages of ovarian cancer (Figure 5D). Here, WFDC2 is linked to ovarian cancer.